Statement re Hermal

15th Jan 2007 14:30

15 January 2007 STATEMENT RE HERMAL

Reckitt Benckiser plc (RB.L) today announced that it is conducting a full strategic review of all options for the Hermal prescription skincare business acquired as part of Boots Healthcare International (BHI) in January 2006. Goldman Sachs has been appointed to advise the Company.

Reckitt Benckiser is seeking an early resolution of all options in order to cause as little disruption to the business as possible.

Hermal represents approximately 1% of Reckitt Benckiser plc's total net revenues and operating profits.

For Further Information

Tom Corran Reckitt Benckiser +44 (0) 1753 217800

Senior Vice President, Investor Relations & Corporate Communications

Fiona Fong Reckitt Benckiser +44 (0) 1753 217800

Head of Corporate Communications

RECKITT BENCKISER PLC

---

Related Shares:

RB..L